$151.83
2.46%
Downside
Day's Volatility :5.25%
Upside
2.86%
41.38%
Downside
52 Weeks Volatility :43.19%
Upside
3.08%
Period | Illumina Inc. | Sector (Health Care) | Index (NASDAQ Composite) |
---|---|---|---|
3 Months | 25.38% | 1.4% | 17.2% |
6 Months | 34.58% | 3.8% | 16.2% |
1 Year | 32.6% | 15.3% | 39.2% |
3 Years | -62.25% | 11.4% | 18.9% |
Market Capitalization | 24.7B |
Book Value | $13.37 |
Earnings Per Share (EPS) | -9.77 |
PEG Ratio | 0.73 |
Wall Street Target Price | 161.91 |
Profit Margin | -36.11% |
Operating Margin TTM | 21.11% |
Return On Assets TTM | 1.06% |
Return On Equity TTM | -39.51% |
Revenue TTM | 4.4B |
Revenue Per Share TTM | 27.65 |
Quarterly Revenue Growth YOY | -3.5000000000000004% |
Gross Profit TTM | 3.1B |
EBITDA | 536.0M |
Diluted Eps TTM | -9.77 |
Quarterly Earnings Growth YOY | -0.96 |
EPS Estimate Current Year | 4.02 |
EPS Estimate Next Year | 4.4 |
EPS Estimate Current Quarter | 0.88 |
EPS Estimate Next Quarter | 0.94 |
What analysts predicted
Upside of 4.3%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.3B | ↑ 21.11% |
Net Income | 826.0M | ↑ 13.77% |
Net Profit Margin | 24.78% | ↓ 1.6% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.5B | ↑ 6.3% |
Net Income | 1.0B | ↑ 21.31% |
Net Profit Margin | 28.28% | ↑ 3.5% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.2B | ↓ 8.58% |
Net Income | 656.0M | ↓ 34.53% |
Net Profit Margin | 20.25% | ↓ 8.03% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 4.5B | ↑ 39.73% |
Net Income | 762.0M | ↑ 16.16% |
Net Profit Margin | 16.84% | ↓ 3.41% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 4.6B | ↑ 1.28% |
Net Income | -4.4B | ↓ 677.95% |
Net Profit Margin | -96.07% | ↓ 112.91% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.5B | ↓ 1.75% |
Net Income | -1.2B | ↓ 73.64% |
Net Profit Margin | -25.78% | ↑ 70.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 0.28% |
Net Income | 3.0M | ↓ 102.14% |
Net Profit Margin | 0.28% | ↑ 13.2% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 8.19% |
Net Income | -234.0M | ↓ 7900.0% |
Net Profit Margin | -19.9% | ↓ 20.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↓ 4.85% |
Net Income | -754.0M | ↑ 222.22% |
Net Profit Margin | -67.38% | ↓ 47.48% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 0.27% |
Net Income | -176.0M | ↓ 76.66% |
Net Profit Margin | -15.69% | ↑ 51.69% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↓ 4.1% |
Net Income | -126.0M | ↓ 28.41% |
Net Profit Margin | -11.71% | ↑ 3.98% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 3.35% |
Net Income | -2.0B | ↑ 1477.78% |
Net Profit Margin | -178.78% | ↓ 167.07% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 7.0B | ↑ 32.38% |
Total Liabilities | 3.1B | ↑ 29.05% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 7.3B | ↑ 5.13% |
Total Liabilities | 2.7B | ↓ 13.2% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 7.6B | ↑ 3.68% |
Total Liabilities | 2.9B | ↑ 6.96% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 15.2B | ↑ 100.62% |
Total Liabilities | 4.5B | ↑ 54.86% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 12.3B | ↓ 19.48% |
Total Liabilities | 5.7B | ↑ 26.27% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 10.1B | ↓ 17.47% |
Total Liabilities | 4.4B | ↓ 22.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.8B | ↓ 3.6% |
Total Liabilities | 5.1B | ↓ 9.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.8B | ↓ 0.31% |
Total Liabilities | 5.2B | ↑ 1.97% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.1B | ↓ 14.03% |
Total Liabilities | 4.2B | ↓ 19.06% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.1B | ↓ 0.11% |
Total Liabilities | 4.4B | ↑ 3.36% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 10.0B | ↓ 0.7% |
Total Liabilities | 4.3B | ↓ 1.37% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 6.1B | ↓ 39.43% |
Total Liabilities | 4.6B | ↑ 7.87% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 30.51% |
Investing Cash Flow | -1.8B | ↑ 747.2% |
Financing Cash Flow | 594.0M | ↓ 437.5% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↓ 7.97% |
Investing Cash Flow | 745.0M | ↓ 141.09% |
Financing Cash Flow | -897.0M | ↓ 251.01% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 2.76% |
Investing Cash Flow | -554.0M | ↓ 174.36% |
Financing Cash Flow | -766.0M | ↓ 14.6% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 545.0M | ↓ 49.54% |
Investing Cash Flow | -1.1B | ↑ 92.96% |
Financing Cash Flow | -51.0M | ↓ 93.34% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 392.0M | ↓ 28.07% |
Investing Cash Flow | -591.0M | ↓ 44.71% |
Financing Cash Flow | 1000.0M | ↓ 2060.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 10.0M | ↓ 93.2% |
Investing Cash Flow | -56.0M | ↓ 45.1% |
Financing Cash Flow | -473.0M | ↓ 149.48% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 105.0M | ↑ 950.0% |
Investing Cash Flow | -37.0M | ↓ 33.93% |
Financing Cash Flow | -3.0M | ↓ 99.37% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 139.0M | ↑ 32.38% |
Investing Cash Flow | -146.0M | ↑ 294.59% |
Financing Cash Flow | -707.0M | ↑ 23466.67% |
Sell
Neutral
Buy
Illumina Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Illumina Inc. | 7.94% | 34.58% | 32.6% | -62.25% | -48.58% |
Idexx Laboratories, Inc. | -10.37% | -12.46% | 0.22% | -33.24% | 60.91% |
Agilent Technologies Inc. | -4.25% | -2.47% | 24.64% | -14.39% | 81.5% |
Thermo Fisher Scientific, Inc. | -6.54% | -2.3% | 21.87% | -10.38% | 90.67% |
Danaher Corp. | -7.82% | -0.4% | 24.97% | -17.78% | 84.21% |
Iqvia Holdings Inc. | -1.82% | -3.44% | 10.58% | -12.03% | 60.51% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Illumina Inc. | 91.22 | NA | 0.73 | 4.02 | -0.4 | 0.01 | NA | 13.37 |
Idexx Laboratories, Inc. | 40.05 | 40.0 | 4.38 | 10.56 | 0.59 | 0.23 | NA | 19.72 |
Agilent Technologies Inc. | 29.07 | 29.07 | 3.01 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
Thermo Fisher Scientific, Inc. | 34.96 | 34.85 | 2.13 | 21.69 | 0.13 | 0.05 | 0.0 | 128.08 |
Danaher Corp. | 46.73 | 46.74 | 2.94 | 7.5 | 0.08 | 0.04 | 0.0 | 71.03 |
Iqvia Holdings Inc. | 27.61 | 27.61 | 1.06 | 11.15 | 0.22 | 0.05 | NA | 38.37 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Illumina Inc. | Buy | $24.7B | -48.58% | 91.22 | -36.11% |
Idexx Laboratories, Inc. | Buy | $33.9B | 60.91% | 40.05 | 22.53% |
Agilent Technologies Inc. | Buy | $40.3B | 81.5% | 29.07 | 21.75% |
Thermo Fisher Scientific, Inc. | Buy | $213.4B | 90.67% | 34.96 | 14.48% |
Danaher Corp. | Buy | $179.0B | 84.21% | 46.73 | 16.39% |
Iqvia Holdings Inc. | Buy | $38.6B | 60.51% | 27.61 | 9.17% |
Insights on Illumina Inc.
Revenue is down for the last 2 quarters, 1.11B → 1.08B (in $), with an average decrease of 2.9% per quarter
Netprofit is up for the last 2 quarters, -1.98B → 705.0M (in $), with an average increase of 382.0% per quarter
In the last 3 years, Illumina Inc. has experienced a drawdown of -62.8%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 47.6%
BlackRock Inc
Vanguard Group Inc
Baillie Gifford & Co Limited.
State Street Corp
Loomis, Sayles & Company LP
Morgan Stanley - Brokerage Accounts
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Organization | Illumina Inc. |
Employees | 10590 |
CEO | Mr. Jacob Thaysen Ph.D. |
Industry | Health Technology |